Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.
Shitara K, et al.
Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098.
Cancer Sci. 2016.
PMID: 27712015
Free PMC article.
Clinical Trial.